Gil Mor, page-26

IMO, the $33m that can potentially be raised from the 30c December 2015 options is crucial going forward as pre trial pre requisites and clinical trial phases going forward are very costly and lengthy procedures and the $40m plus cash at present will fall well short of what will be required over the next few years of human trials

The path is to develop drugs to work with chemotherapy to fight cancer or develop new drugs . It will always come down to toxicity as hundreds of patients will need to be monitored over many years

Then there is non oncology which is much more expensive

Eli Lilly latest trial on Alzheimer's.

''It's a high risk, high reward bet by Eli Lilly. Phase III trials are expensive, costing north of $100 million by themselves. Arfaei said he wouldn't be surprised if the overall cost of development for this program is more than $1 billion from beginning to potential approval. ''

http://money.cnn.com/2015/07/21/investing/alzheimers-eli-lilly-drugs/


DYOR